

Question Time & Summer BBQ

Biographies

Professor Chris Packard (Chair)

R&D Director, North Glasgow University Hospitals NHS Greater Glasgow & Clyde

Chris Packard is R & D Director of North Glasgow University Hospitals NHS Greater Glasgow & Clyde. Over his career he has focussed on two aspects of atherosclerosis research, lipoprotein metabolism and how it is affected by diets and drugs, and large scale clinical trials of lipid lowering agents. More recently his interest has widened to include investigations of emerging risk factors for coronary heart disease and the consequences of social deprivation for health.

Chris is principal investigator of the ongoing pSoBid study, an epidemiological study of the psychosocial and biological determinants of ill health and premature CHD in deprived communities in the east end of Glasgow. Outside the lab Chris is active in local and national initiatives to promote health and wealth gains from medical research.

He has published widely on the kinetics of apolipoprotein B and apolipoprotein A metabolism. Key contributions include evaluation of the role of the LDL receptor *in vivo*, the discovery of metabolic channelling in the apoB lipoprotein delipidation cascade, and the formulation of models to explain the generation of small, dense LDL. More recent research has focussed on the metabolic consequences of insulin resistance and the causes of the dyslipidaemia in metabolic syndrome. As study director and one of the main investigators of the West of Scotland Coronary Prevention Study (WOSCOPS) and the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), Chris helped establish the evidence base for statin use in CHD prevention. These trials provide confidence that statins are beneficial in primary prevention and in older adults and reveal a consistency of treatment effect that encourages their widespread use.

Mr David Burns

Chief Executive Officer, Renishaw Diagnostics Ltd

As CEO of Renishaw Diagnostics of Glasgow, David has more than twenty years of North American and International experience as a sales, marketing and business development professional with companies in the life sciences field.

Prior to joining Renishaw Diagnostics, David held previous senior leadership positions in the US and Canada with CynTellect Inc. as VP Sales and Marketing and Chief Operating Officer, GE Healthcare Life Sciences (formerly Amersham Biosciences) where he filled the roles of Head of Strategic Growth and VP Commercial Alliances. Prior to that, he was CEO of Imaging Research Inc. in Ontario, Canada which was acquired by Amersham in 2003.

David joined Imaging Research and the Amersham group from a role as Vice-President Business Development and Marketing at Packard-BioSignal Inc. in Montreal, Quebec. David's prior experience included other executive business development and marketing positions with Packard Bioscience in the USA and Netherlands and in scientific sales with Pharmacia/LKB in the UK.

Dr Kevin Cullen

Director of Research & Enterprise, University of Glasgow

Kevin was appointed Director of Research and Enterprise (R&E) at the University of Glasgow in October 2003 and is responsible for directing activities in order to achieve the research and enterprise objectives of the University.

He joined R&E in 1999 from Heriot-Watt University, where he held responsibility for devising and implementing the University's commercialisation strategy. He has also worked for Procter & Gamble in the UK and Belgium, in the fields of technical brand management, product development, and technology development covering Europe, North Africa, and the Middle East. He has acted as an external expert and consultant in a number of international projects, particularly focussed on Knowledge Transfer. His qualifications include a PhD in physical-organic chemistry from the University of Edinburgh.

Kevin is currently Vice President for Metrics and Surveys for ASTP (Association of European Science & Technology Transfer Professionals) and Assistant Vice President for Metrics and Surveys for AUTM (Association of University Technology Managers), the world's largest academic Technology Transfer association. Kevin is Past President of UNICO (the UK Technology Transfer Association) and has served as both Vice President for Metrics and Surveys and Vice President for Membership on the Board of AUTM

Dr Cameron Macdonald

Managing Director, Controlled Therapeutics

Cameron Macdonald is Managing Director of Controlled Therapeutics (Scotland) Ltd and Executive Vice President of its parent company, Cytokine PharmaSciences Inc, King of Prussia, PA, USA.

Previous to this he was CEO of Scottish Health Innovations Ltd (SHIL), a private company established to identify and commercialise innovations arising within the NHS in Scotland. During his time at SHIL he helped establish four new companies based on NHS technologies. In one of these, Touch Bionics Ltd, he served as Non-Executive Director and then Chairman. Before SHIL he was CEO of two start-up biotech companies, Gene Expression Technologies Ltd and PanTherix Ltd.

Prior to returning to Scotland in 1999 he held a number of senior management and main Board roles in the pharmaceutical industry. The greater part of this was in Hoechst Roussel UK (now part of Sanofi Aventis) where he held the posts of R&D Director and then Marketing and Sales Director. Following Hoechst Roussel he was Executive Director responsible for Business Development and Strategy for a major CRO.

Mr John Waddell

Chief Executive, Archangel Informal Investment Ltd

John Waddell is a Director and Chief Executive of Archangel Informal Investment Ltd. He has responsibility for reviewing all new investment proposals as well as managing fundraising and deal syndication. John is also often involved in giving strategic advice to the portfolio of 24 companies, of which 9 are in Life Sciences. He is a lawyer with wide experience in industry and corporate finance in the UK and abroad.

He sits on the boards of two Archangel portfolio companies, Lab901 Ltd and CXR Biosciences Ltd, and on the advisory boards of the Amadeus & Angels Seed Fund and Seraphim Capital, in both of which Archangels have invested.

He is a director of Northern 3VCT Plc and an independent medical start up. .

Mr Gerard Kelly

Senior Director, Scottish Enterprise Investments

Gerard leads Scottish Enterprise Investments (SEi), the risk capital arm of Scottish Enterprise. Since 2003 SEi has raised £235m of capital, investing £100m in 250 of Scotland's most exciting young technology companies, and leveraging a further £200m+ of private capital from a range of local and international investors into those companies. These achievements were recognised in 2009 when SEi received the prestigious "Insider Deal Making Team of the Year" award.

Gerard moved to Scottish Enterprise from the Confederation of British Industry in 2000 where he had been Assistant Director for Scotland for two years. Before joining CBI he headed a major joint private/public sector taskforce looking at ways to better commercialise the science and technology produced by Scotland's research base. This position followed several years working in various business sectors. During that time Gerard also acted as an expert consultant for the World Bank on a number of reconstruction projects in emerging Eastern European economies.

Gerard is current the chairman of ITI Scotland, a board member of PROSPEKT and a director of the Scottish Investment Bank.
